Pharmaceuticals

Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08:00 a.m. Finnish time

HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, on...

2020-11-27 14:30 1511

European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany, Nov. 27, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...

2020-11-27 08:42 700

Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness

* Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines * Two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative SHANGHAI, Nov. 26, 2020 ...

2020-11-26 16:44 1086

Interim report, May-October 2020/21

STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony...

2020-11-26 15:01 3251

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 14:04 2116

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 10:32 940

Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone

SIR-Spheres® new drug application is accepted by the National Medical Products  Administration of China WOBURN, Mass., Nov. 26, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareh...

2020-11-26 01:17 917

Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical ...

2020-11-25 08:27 736

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in theISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SE...

2020-11-25 08:00 788

RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences

TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferen...

2020-11-25 07:00 1261

Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

BARCELONA, Spain, Nov. 25, 2020 /PRNewswire/ -- AlmirallShare , the open innovation platform of Almirall, S.A. (ALM),  announces two new collaborations with theUniversity of South Australia and the Fundació Institut de Recerca de ...

2020-11-25 06:00 3105

The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets

RDIF continues expanding existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021 MOSCOW, Nov. 25, 2020 * The cost of one dose of the Sputnik V vaccine for international markets will be less than$10. Sputnik V is a two dose ...

2020-11-25 04:38 717

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose

MOSCOW, Nov. 24, 2020 /PRNewswire/ -- * The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). * Calculation was based on the analysis of data on volunteers (n = 18,794) ...

2020-11-24 22:14 745

New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials

Pharmaceutical clinical industry report highlights factors impacting volume, cost and duration of Phase II trials LONDON, Nov. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced t...

2020-11-24 16:05 3523

Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19

AUCKLAND, New Zealand, Nov. 24, 2020 /PRNewswire/ -- Koru Lifescience, drug discovery, and advanced formulation research laboratory inAuckland, New Zealand , has identified several known drug compounds of value in their study for a treatment of Covid-19. The study reports shall be published after ...

2020-11-24 04:35 506

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL...

2020-11-23 21:28 4810

Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud

LONDON and REDWOOD SHORES, Calif., Nov. 23, 2020 /PRNewswire/ -- The Tony Blair Institute (TBI) and Oracle have brought cloud technology toAfrica to manage public health programs. Initially,Ghana, Rwanda, and Sierra Leone will use the newOracle Health Management System to create electronic health...

2020-11-23 21:05 3286

GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial

SEOUL, Nov. 23, 2020 /PRNewswire/ -- GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease of lead candi...

2020-11-23 20:00 733

Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition

BAD HOMBURG, Germany, Nov. 23, 2020 /PRNewswire/ -- Evidence indicates that omega-3 (ω-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health ca...

2020-11-23 19:00 745

Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2020-11-23 18:34 5318
12345 ... 92